Please use this identifier to cite or link to this item:
Title: Metabolic studies of a patient harbouring a novel S487L mutation in the catalytic subunit of AMPK
Authors: Arita, Juliana Harumi [UNIFESP]
Barros, Mario H.
Ravagnani, Felipe Gustavo
Ziosi, Marcello
Sanches, Livia Rentas
Picosse, Fabíola Rosa [UNIFESP]
Lopes, Tania Oliveira
Aguiar, Patricia de Carvalho [UNIFESP]
Macabelli, Carolina Habermann
Chiaratti, Marcos R.
Pedroso, Jose Luiz [UNIFESP]
Quinzii, Catarina M.
Barsottini, Orlando Graziani Povoas [UNIFESP]
Ferreiro-Barros, Claudia Cristina [UNIFESP]
Keywords: AMPK
Neurological impairment
Oxidative phosphorylation
Mitochondrial diseases
Issue Date: 2018
Publisher: Elsevier Science Bv
Citation: Biochimica Et Biophysica Acta-Molecular Basis Of Disease. Amsterdam, v. 1864, n. 5, p. 1896-1903, 2018.
Abstract: AMP-activated protein kinase (AMPK) regulates many different metabolic pathways in eukaryote cells including mitochondria biogenesis and energy homeostasis. Here we identify a patient with hypotonia, weakness, delayed milestones and neurological impairment since birth harbouring a novel homozygous mutation in the AMPK catalytic alpha-subunit 1, encoded by the PRKAA1 gene. The homozygous mutation p.S487L in isoform 1 present in the patient is in a cryptic residue for AMPK activity. In the present study, we performed the characterization of mitochondrial respiratory properties of the patient, in comparison to healthy controls, through the culture of skin fibroblasts in order to understand some of the cellular consequences of the PRKAA1 mutation. In these assays, mitochondrial respiratory complex I showed lower activity, which was followed by a decrement in the mtDNA copy number, which is a probable consequence of the lower expression of PGC-1 alpha and PRKAA1 itself as measured in our quantitative PCRs experiments. Confirming the effect of the patient mutation in respiration, transfection of patient fibroblasts with wild type PRKAA1 partially restore complex I level. The preliminary clinic evaluations of the patient suggested a metabolic defect related to the mitochondrial respiratory function, therefore treatment with CoQ10 supplementation dose started four years ago and a clear improvement in motor skills and strength has been achieved with this treatment.
ISSN: 0925-4439
Other Identifiers:
Appears in Collections:Artigo

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.